Cargando…

Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway

Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanwei, Gong, Qian, Guo, Wenjin, Kan, Xingchi, Xu, Dianwen, Ma, He, Fu, Shoupeng, Liu, Juxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032361/
https://www.ncbi.nlm.nih.gov/pubmed/29904013
http://dx.doi.org/10.3390/ijms19061770
_version_ 1783337490456772608
author Li, Yanwei
Gong, Qian
Guo, Wenjin
Kan, Xingchi
Xu, Dianwen
Ma, He
Fu, Shoupeng
Liu, Juxiong
author_facet Li, Yanwei
Gong, Qian
Guo, Wenjin
Kan, Xingchi
Xu, Dianwen
Ma, He
Fu, Shoupeng
Liu, Juxiong
author_sort Li, Yanwei
collection PubMed
description Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis.
format Online
Article
Text
id pubmed-6032361
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60323612018-07-13 Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway Li, Yanwei Gong, Qian Guo, Wenjin Kan, Xingchi Xu, Dianwen Ma, He Fu, Shoupeng Liu, Juxiong Int J Mol Sci Article Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis. MDPI 2018-06-14 /pmc/articles/PMC6032361/ /pubmed/29904013 http://dx.doi.org/10.3390/ijms19061770 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Yanwei
Gong, Qian
Guo, Wenjin
Kan, Xingchi
Xu, Dianwen
Ma, He
Fu, Shoupeng
Liu, Juxiong
Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title_full Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title_fullStr Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title_full_unstemmed Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title_short Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway
title_sort farrerol relieve lipopolysaccharide (lps)-induced mastitis by inhibiting akt/nf-κb p65, erk1/2 and p38 signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032361/
https://www.ncbi.nlm.nih.gov/pubmed/29904013
http://dx.doi.org/10.3390/ijms19061770
work_keys_str_mv AT liyanwei farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT gongqian farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT guowenjin farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT kanxingchi farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT xudianwen farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT mahe farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT fushoupeng farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway
AT liujuxiong farrerolrelievelipopolysaccharidelpsinducedmastitisbyinhibitingaktnfkbp65erk12andp38signalingpathway